Intracavitary Radiotherapy: Applications and Insights into Phosphorus-32 Colloidal Chromic Phosphate
Phosphorus-32 Colloidal Chromic Phosphate delivers precise beta radiation for treating malignant effusions and cystic tumours.
Radiotheranostics is an advanced approach in modern oncology that combines diagnostic imaging and targeted radionuclide therapy within a unified strategy. It uses radiolabelled compounds that bind selectively to tumour-associated targets, allowing clinicians to first visualise disease distribution and then deliver therapeutic radiation to the same molecular sites. This integrated model supports personalised treatment planning by confirming adequate tumour uptake before therapy. Radiotheranostics has shown particular promise in prostate and neuroendocrine cancers, improving precision while limiting exposure to healthy tissue. Linking diagnosis directly with treatment enables real-time assessment of response and adaptive care. Ongoing advances in molecular targeting continue to expand its role in precision cancer medicine.
Phosphorus-32 Colloidal Chromic Phosphate delivers precise beta radiation for treating malignant effusions and cystic tumours.
Lutetium-177 XT033 combines PSMA targeting and Evans blue technology to improve metabolic stability and therapeutic effectiveness.
Lutetium-177 Vipivotide Tetraxetan is a groundbreaking radioligand therapy targeting PSMA, offering precise tumour treatment with minimal damage to healthy tissues.
Lutetium-177 TLX250 targets CA-IX-expressing tumours, providing a selective radiotherapy approach for treating advanced renal cell carcinoma.
Lutetium-177 Satoreotide Tetratexan is a radiopharmaceutical targeting somatostatin receptors, providing advanced therapeutic options for neuroendocrine neoplasms effectively.
Lutetium-177 Rosopatamab is a radiopharmaceutical therapy combining targeted monoclonal antibodies with beta-emitting radioactive particles.
Lutetium-177 RM2 leverages GRPR targeting to deliver therapeutic beta radiation, minimising off-target effects and enhancing prostate cancer treatment outcomes.
Lutetium-177 Rituximab offers a targeted radiopharmaceutical solution, delivering beta radiation to CD20-positive cells, ensuring effective and precise lymphoma therapy.
RhPSMA revolutionises prostate cancer management with dual labelling, enabling precise imaging and effective targeted radiotherapy options.
Lutetium-177 PSMA-R2 is a urea-based therapeutic agent targeting PSMA, effectively treating advanced prostate cancer patients.
Lutetium-177 PSMA-ALB-56 is an innovative treatment optimising prostate cancer therapy through targeted radiopharmaceutical advancements.
Lutetium-177 PNT6555, a FAP-targeted radiopharmaceutical, combines precision therapy with beta radiation for tumour-specific treatment.
Lutetium-177 PNT2002 offers targeted radiotherapy for prostate cancer, combining precise tumour targeting with therapeutic and diagnostic capabilities.
Lutetium-177 Pentixather targets CXCR4-expressing tumours, delivering precise beta radiation therapy to eliminate malignant cells effectively.
Lutetium-177 Oxodotreotide Treatment offers targeted neuroendocrine tumour therapy, improving progression-free survival and patient outcomes significantly.
Lutetium-177 MVT-1075 radioimmunotherapy targets pancreatic cancer by utilising CA19-9 specificity, sialyl-Lewis a binding, and precision radiation delivery.
Lutetium-177 Ludotadipep targets PSMA with enhanced stability, specificity, and reduced side-effects, revolutionising prostate cancer treatment.
Lutetium-177 LNC1010, a radiolabelled therapy, targets somatostatin receptors, delivering precise treatment with minimal side effects.
A novel radiolabelled drug, Lutetium-177 LNC1004, targets fibroblast activation protein, transforming cancer therapy through precision and innovation.
Betalutin combines the precision of CD37-targeting antibody Lilotomab with Lutetium-177, offering targeted and effective haematological cancer treatment.
Targeting glioblastoma with Lutetium-177 ITM-31 offers precise intracavitary treatment, reducing recurrence by specifically addressing residual cancer cells post-surgery.
Lutetium-177 iPSMA revolutionises prostate cancer treatment, delivering targeted beta radiation to metastatic cells with precision and minimal side effects.
Targeting Neurotensin Receptor-1 with Lutetium-177 IPN-01087 demonstrates promising precision therapy, delivering beta radiation for treating invasive cancers like ductal pancreatic adenocarcinoma.
Advancing prostate cancer treatment, Lutetium-177 HTK03170 and Gallium-68 HTK03149 enable targeted PSMA therapy, improving diagnosis and therapeutic outcomes.
Lutetium-177 FAPI-04 revolutionises cancer treatment by precisely targeting cancer-associated fibroblasts, enabling dual imaging and radiotherapy functionalities for enhanced outcomes.
Revolutionising cancer therapy, Lutetium-177 FAP-2286 offers precise diagnostics and targeted treatment, addressing solid tumours and fibrotic conditions effectively.
Lutetium-177 EDTMP provides a cost-effective, accessible, and efficacious alternative for bone pain palliation in metastatic cancer patients.
Lutetium-177 Edotreotide revolutionises neuroendocrine tumour treatment through targeted radioligand therapy, enhancing precision and improving patient outcomes.
Lutetium-177 EB-PSMA-617 represents an innovative radioligand therapy optimising tumour retention and therapeutic outcomes in metastatic prostate cancer.
Lutetium-177 DTPA-Omburtamab offers hope in neuroblastoma treatment by precisely targeting B7-H3, delivering localised radiation while sparing healthy tissues.